Chromosome 21 BACE2 haplotype associates with Alzheimer's disease: A two-stage study

Genetic linkage studies have provided evidence for a late-onset Alzheimer's disease (AD) susceptibility locus on chromosome 21q. We have tested, in a two-stage association study, whether allelic or haplotype variation of the beta-amyloid cleaving enzyme-2 (BACE2) locus on chromosome 21q affects the risk of late-onset AD. In stage-1, an unselected population-based sample of Finns aged 85 years or over (n = 515) was analysed. Neuropathologic examination including beta-amyloid load quantification was possible in over 50% (n = 264) of these subjects. AD patients (n = 100) and controls (n = 48) were defined by modified neuropathological NIA-RI criteria. Positive associations were taken as a hypothesis, and tested in stage-2 using 483 AD families from the USA. Four single nucleotide polymorphisms (SNPs) of BACE2 gene were tested in stage-1. A SNP close to exon-6 was associated with neuropathologically verified AD (p = 0.02) and also with beta-amyloid load in non-selected autopsied subjects after conditioning with APOE genotype (p = 0.001). In haplotype analysis a specific, relatively common haplotype (H5) was found to associate with AD (p = 0.004) and a second haplotype (H7) showed a weaker association with protection against AD (p = 0.04). In stage-2, the SNP association was not replicated, whereas the haplotype H5 association was replicated (p = 0.004) and a trend to association was found with the putative protective haplotype H7 (two-sided p = 0.08). BACE2 haplotype association with AD in two independent datasets provides further evidence for an AD susceptibility locus on chromosome 21q within or close to BACE2.